POS1330 LUNG ULTRASOUND FOR THE FOLLOW-UP OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE TREATED WITH NINTEDANIB: OUTCOMES AND COMPARISONS WITH OTHER ASSESSMENT TOOLS

Background Nintedanib (NIN) is an antifibrotic drug used to slow the progression of systemic sclerosis-related interstitial lung disease (SSc-ILD), reducing decline in forced vital capacity (FVC). High-resolution chest tomography (HRCT) gold standard imaging technique assess SSc-ILD, whereas ultrasound (LUS) a useful and repeatable non-invasive tool which increasingly clinical practice. Objectives The aim this work was investigate usefulness LUS during follow-up SSc-ILD patients treated with NIN. Methods Adult SSc starting NIN for ILD were enrolled followed 12 months. performed at baseline quarterly on 55 antero-posterior spaces, evaluating pleural line irregularities (PLI; semi-quantitative score 0-1-2) number B-lines (BL), according OMERACT definition. FVC investigated every six months, HRCT following patient-reported outcomes administered quarterly: Leicester cough questionnaire St.George respiratory questionnaire. During follow-up, all aforementioned investigations assessed stability, improvement, or worsening from baseline, then concordance variations. Results Ten (70% female, mean age 62±10.9 years) enrolled. One patient had prematurely discontinue due unbearable gastrointestinal adverse effects. other 9 achieving stabilization 87.5% cases. PLI BL both showed declining trend over time (Figure 1), 12-months significant overall reduction (p=0.02 PLI; p<0.01 BL). At final evaluation, improved 55.5% cases stable rest, resulted worsened 62.5% rest. these two techniques very low (12.5%). quite good (61.5% 46.1% Moreover, variations greater (69.2% 42.3%, respectively) than (35.7% 28.5%, respectively). Conclusion We Changes fairly closely reflected functional subjective patients. correlation questionnaires. seems progress regardless efficacy function, therefore could be monitoring receiving Figure 1. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.